1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => FreeToRead
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


  
    
















































































































    Reproducibility of Three Whole-Brain N-Acetylaspartate Decline Cohorts in Relapsing-Remitting Multiple Sclerosis | American Journal of Neuroradiology  
    


















    





























    
  
  




    
    

  

      


    

      

  
  
  

    

  

    

  

                
    

      

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



    

  


  


  


  
  
  
  
  
  

  	      


    
      

    
  
    
        
    

  

    
                        

  

                
    

      

	  

		
		

			

			  

  
      
  
  

    

  
  
      
Research ArticleBRAIN

  
      

  
      
Reproducibility of Three Whole-Brain N-Acetylaspartate Decline Cohorts in Relapsing-Remitting Multiple Sclerosis
  
    	
O. Gonen, T.A. Oberndorfer, M. Inglese, J.S. Babb, J. Herbert and R.I. Grossman

  
    	
American Journal of Neuroradiology February 2007,  28 (2) 267-271; 

  
  
  



  


  
  



			

		

	
	
 	
	  
  

		
		

			

			  

  
      
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    
References
  1. ↵
    Hauser SL. Multiple sclerosis and other demyelinating diseases. In: Isselbacher KJ, Wilson JD, Martin JB, et al. Harrison’s Principles of Internal Medicine. New York: McGraw-Hill,1994 :2287–95
  2. ↵
    Bryant J, Clegg A, Milne R. Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: is there good quality evidence on effectiveness and cost? J Neurol Neurosurg Psychiatry 2001;70:574–79
    Abstract/FREE Full Text
  3. ↵
    Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112:1419–28
    Abstract/FREE Full Text
  4. Weinshenker BG, Rice GP, Noseworthy JH, et al. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain 1991;114:1057–67
    Abstract/FREE Full Text
  5. Kremenchutzky M, Cottrell D, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999;122:1941–50
    Abstract/FREE Full Text
  6. ↵
    Weinshenker BG. The natural history of multiple sclerosis: update 1998. Semin Neurol 1998;18:301–07
    PubMedWeb of Science
  7. ↵
    Confavreux C, Vukusic S. Natural history of multiple sclerosis: implications for counselling and therapy. Curr Opin Neurol 2002;15:257–66
    CrossRefPubMedWeb of Science
  8. ↵
    Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980;103:281–300
    FREE Full Text
  9. ↵
    Bjartmar C, Wujek JR, Trapp BD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci 2003;206:165–71
    CrossRefPubMedWeb of Science
  10. Bjartmar C, Battistuta J, Terada N, et al. N-acetylaspartate is an axon-specific marker of mature white matter in vivo: a biochemical and immunohistochemical study on the rat optic nerve. Ann Neurol 2002;51:51–58
    CrossRefPubMedWeb of Science
  11. ↵
    Bjartmar C, Kidd G, Mork S, et al. Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 2000;48:893–901
    CrossRefPubMedWeb of Science
  12. ↵
    De Stefano N, Narayanan S, Francis GS, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001;58:65–70
    CrossRefPubMedWeb of Science
  13. ↵
    Birken DL, Oldendorf WH. N-acetyl-L-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1989;13:23–31
    CrossRefPubMedWeb of Science
  14. ↵
    Danielsen EA, Ross B. In: Magnetic Resonance Spectroscopy Diagnosis of Neurological Diseases. New York: Marcel Dekker,1999
  15. Arnold DL, de Stefano N, Matthews PM, et al. N-acetylaspartate: usefulness as an indicator of viable neuronal tissue. Ann Neurol 2001;50:823 ; discussion 824–25
    PubMedWeb of Science
  16. ↵
    Baslow MH. Functions of N-acetyl-L-aspartate and N-acetyl-L-aspartylglutamate in the vertebrate brain: role in glial cell-specific signaling. J Neurochem 2000;75:453–59
    CrossRefPubMedWeb of Science
  17. ↵
    Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies. Neuroscience 1991;45:37–45
    CrossRefPubMedWeb of Science
  18. Jenkins BG, Klivenyi P, Kustermann E, et al. Nonlinear decrease over time in N-acetyl aspartate levels in the absence of neuronal loss and increases in glutamine and glucose in transgenic Huntington’s disease mice. J Neurochem 2000;74:2108–19
    CrossRefPubMedWeb of Science
  19. ↵
    Moffett JR, Namboodiri MA, Cangro CB, et al. Immunohistochemical localization of N-acetylaspartate in rat brain. Neuroreport 1991;2:131–34
    PubMedWeb of Science
  20. ↵
    Baslow MH. N-acetylaspartate in the vertebrate brain: metabolism and function. Neurochem Res 2003;28:941–53
    CrossRefPubMedWeb of Science
  21. ↵
    Baslow MH, Resnik TR. Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms. J Mol Neurosci 1997;9:109–25
    CrossRefPubMedWeb of Science
  22. ↵
    Ross BD, Bluml S. Magnetic resonance spectroscopy of the human brain. Anat Rec 2001;265:54–84
    CrossRefPubMed
  23. ↵
    Gonen O, Moriarty DM, Li BS, et al. Relapsing-remitting multiple sclerosis and whole-brain N-acetylaspartate measurement: evidence for different clinical cohorts initial observations. Radiology 2002;225:261–68
    PubMedWeb of Science
  24. ↵
    Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227–31
    CrossRefPubMedWeb of Science
  25. ↵
    De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001;22:529–39
    CrossRefPubMedWeb of Science
  26. ↵
    Gonen O, Viswanathan AK, Catalaa I, et al. Total brain N-acetylaspartate concentration in normal, age-grouped females: quantitation with non-echo proton NMR spectroscopy. Magn Reson Med 1998;40:684–89
    PubMedWeb of Science
  27. Gonen O, Catalaa I, Babb JS, et al. Total brain N-acetylaspartate: a new measure of disease load in MS. Neurology 2000;54:15–19
    Abstract/FREE Full Text
  28. ↵
    Gonen O, Grossman RI. The accuracy of whole brain N-acetylaspartate quantification. Magn Reson Imaging 2000;18:1255–58
    CrossRefPubMedWeb of Science
  29. ↵
    Inglese M, Ge Y, Filippi M, et al. Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. Neuroimage 2004;21:1825–29
    CrossRefPubMedWeb of Science
  30. ↵
    Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126:433–37
    Abstract/FREE Full Text
  31. ↵
    Weinshenker BG. Natural history of multiple sclerosis. Ann Neurol 1994;36:S6–S11
  32. ↵
    Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo group. Mult Scler 2002;8:405–09
    Abstract/FREE Full Text
  33. ↵
    Rovaris M, Gambini A, Gallo A, et al. Axonal injury in early multiple sclerosis is irreversible and independent of the short-term disease evolution. Neurology 2005;65:1626–30
    Abstract/FREE Full Text
  34. ↵
    Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576–82
    CrossRefPubMedWeb of Science
  35. ↵
    McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–27
    CrossRefPubMedWeb of Science
  36. Barkhof F, Filippi, M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997;120:2059–69
    Abstract/FREE Full Text
  37. ↵
    Offenbacher H, Fazekas F, Schmidt R, et al. Assessment of MRI criteria for a diagnosis of MS. Neurology 1993;4:905–09
  38. ↵
    Narayanan S, Fu L, Pioro E, et al. Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997;41:385–91
    CrossRefPubMedWeb of Science
  39. De Stefano N, Matthews PM, Fu LQ, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis—results of a longitudinal magnetic resonance spectroscopy study. Brain 1998;121:1469–77
    Abstract/FREE Full Text
  40. ↵
    Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278–85
    CrossRefPubMedWeb of Science
  


  
  



  




  


  
  



  
      
  
  

    
  


  
  



  
      
  
  

     Back to top  


  
  



			

		

		
		

			

			  

  
        
In this issue

    
  
  

    
  


  
  



  
      
  
  

    

  

    

  
      
  
  

    


Advertisement



  



  


  
  



  



  


  
  



  
      
  
  

    

	  
  

		

          

            

  
      
  
  

     Print  


  
  



  
      
  
  

     Download PDF  


  
  



  
      
  
  

    
 Email Article
  


  
  



  
      
  
  

    
 Citation Tools
  


  
  



          

        

        
        

          

            



  
      
  
  

    

  

    

  
      
  
  

    

  
  
  
  
      
Reproducibility of Three Whole-Brain N-Acetylaspartate Decline Cohorts in Relapsing-Remitting Multiple Sclerosis
  
    	
O. Gonen, T.A. Oberndorfer, M. Inglese, J.S. Babb, J. Herbert, R.I. Grossman

  
    	
American Journal of Neuroradiology Feb 2007, 28 (2) 267-271; 

  
  
  



  


  
  



  
      
  
  

    

  
    
  
  
    
  
  
    
  


  


  
  



  
      
  
  

    
del.icio.us logo Twitter logo Facebook logo Mendeley logo
  


  
  



  



  


  
  



  
      
  
  

    
  


  
  



          

        

	
 	
	
	


  


  
  



  
        
Jump to section

    
  
  

    
  


  
  



  
      
  
  

    
  


  
  



			

		

	
	
 	
	
	


    

  



  

                
    

      

  

    

  
      
  
  

    


Advertisement